ISSN: 0443-511
e-ISSN: 2448-5667
Usuario/a
Idioma
Herramientas del artículo
Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión)

Open Journal Systems

Respuesta inmune innata de interferón gamma en pacientes graves positivos a COVID-19 / Innate immune response to interferon gamma in severe Covid-19 positive patients

Fabiola del Rocío Villalobos-Gómez, Anastacio Palacios-Marmolejo, Rogelio Salinas-Gutiérrez, Hugo Enrique Lagunes-Servín

Resumen


Resumen

Introducción: se ha demostrado que el SARS-CoV-2 está asociado con la activación de la inmunidad innata, observándose un aumento de neutrófilos, fagocitos mononucleares y células asesinas naturales, así como una disminución de las células T. El interferón desempeña papeles importantes para restringir los virus y es crucial porque participa tanto en la inmunidad innata como en la adaptativa. El interferón gamma (IFN-γ) es una citocina que cumple un papel fundamental para mantener la homeostasis del organismo, tanto in vitro como in vivo.

Objetivo: se realizó un estudio inmunológico en el que se midieron las concentraciones de IFN-γ en pacientes graves positivos a SARS-CoV-2.

Material y métodos: se trabajaron alrededor de 500 muestras de suero de pacientes con comorbilidad respiratoria similar al inicio de la enfermedad, utilizando como controles a pacientes sanos. Los sueros de las personas positivas a SARS-CoV-2 se procesaron mediante la técnica de ELISA. El tratamiento estadístico de los datos consistió en construir una base de datos con las absorbancias, que luego se transformaron en concentraciones en pg/ml.

Resultados: podemos inferir que la cantidad de expresión de IFN-γ depende de las condiciones del paciente: entre más grave esté el paciente, mayor es la cantidad de expresión de esta citocina, con niveles basales que varían de 0 a 0.5 μg/ml.

Conclusión: se sugiere que la respuesta de IFN-γ es una parte importante para el control de la enfermedad. Se recomiendan terapias eficaces en el tratamiento de la COVID-19, las cuales conducirán a la implementación de enfoques terapéuticos que apunten a contrarrestar el sistema inmunológico, especialmente en las formas más graves de la enfermedad.

 

Abstract

Background: SARS-CoV-2 is associated with the activation of innate immunity, with an observed increase in neutrophils, mononuclear phagocytes, and natural killer cells, as well as a decrease in T cells. Interferon plays important roles in restricting viruses and is crucial because it participates in both innate and adaptive immunity. Gamma interferon (IFN-γ) is a cytokine that plays a fundamental role in maintaining homeostasis in the body, both in vitro and in vivo.

Objective: An immunological study was conducted to measure the concentrations of IFN-γ in severe SARS-CoV-2-positive patients.

Material and methods: Around 500 sera from patients with similar respiratory comorbidities at the onset of the disease were analyzed, using healthy patients as controls. The sera from SARS-CoV-2-positive individuals were processed using the ELISA technique, and the statistical treatment of the data involved creating a database with the absorbance readings, which were then converted into concentrations in pg/ml.

Results: We can infer that the amount of IFN-γ expression depends on the patient's condition; the more severe the patient's condition, the higher the expression of this cytokine compared to their baseline levels, ranging from 0 to 0.5 μg/ml.

Conclusion: It is suggested that the IFN-γ response plays an important role in controlling the disease, and effective therapies are recommended for the treatment of Covid-19, which will lead to the implementation of therapeutic approaches aimed at counteracting the immune system, especially in the more severe forms of the disease.


Palabras clave


COVID-19; Inmunidad; Interferón gamma / COVID-19; Immunity; Interferon gamma

Texto completo:

PDF

Referencias


Senevirathne TH, Wekking D, Swain JWR, et al. COVID-19: From emerging variants to vaccination. Cytokine Growth Factor Rev. 2024;76:127–41.

Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis -A review of current methods. Biosens Bioelectron. el 15 de enero de 2021;172:112752.

Beladiya J, Kumar A, Vasava Y, Parmar K, et al. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials. Rev Med Virol. 2024;34(1):e2507.

Krammer F. The role of vaccines in the COVID-19 pandemic: what have we learned? Semin Immunopathol. 2024;45(4–6):451–68.

Villalobos-Gómez FDR, García-Lorenzana M, Escobedo G, et al. Entamoeba histolytica L220 induces the in vitro activation of macrophages and neutrophils and is modulated by neurotransmitters. Acta Parasitol. 2018;63(2):270–9.

Anjum FR, Anam S, Abbas G, et al. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN- γ as a Novel Antiviral Approach Against COVID-19. Viral Immunol. 2021;34(5):321–9.

Liu W, Zhang S, Wang J. IFN-γ, should not be ignored in SLE. Front Immunol. 2022;13:954706.

Yasukawa K, Saito S, Kubo T, et al. Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses. Vet Dermatol. 2010;21(1):42–9.

Alspach E, Lussier DM, Schreiber RD. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harb Perspect Biol. e2019;11(3):a028480.

Fernández-Rúa JM. Interferón: Hallazgo clave contra infección por coronavirus. biotechmagazineandnews.com. 2020 [citado el 25 de abril de 2020]. Disponible en: https://biotechmagazineandnews.com/interferon-hallazgo-clave-contra-infeccion-por-coronavirus/

Cantell K, Pirhonen J. IFN-gamma enhances production of IFN-alpha in human macrophages but not in monocytes. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 1996;16(6):461–3.

Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95–109.

Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629.

Cremoni M, Allouche J, Graça D, et al. Low baseline IFN-γ response could predict hospitalization in COVID-19 patients. Front Immunol. 2022;13:953502.

Fess LJ, Fell A, O’Toole S, et al. COVID-19 Death Determination Methods, Minnesota, USA, 2020–20221. Emerg Infect Dis. 2024;30(7):1352–60.

Huang TC, Liang KH, Chang TJ, et al. Structure-based approaches against COVID-19. J Chin Med Assoc. 2024;87(2):139.

Hein J, Schellenberg U, Bein G, et al. Quantification of murine IFN-gamma mRNA and protein expression: impact of real-time kinetic RT-PCR using SYBR green I dye. Scand J Immunol. 2001;54(3):285–91.

Palacios-Cruz M, Santos E, Velázquez-Cervantes MA, et al. COVID-19, a worldwide public health emergency. Rev Clin Esp. 2021;221(1):55-61.

Mata-Espinosa DA, Hernández-Pando R. Interferón gamma: aspectos básicos, importancia clínica y usos terapéuticos. Rev Investig Clínica. 2008;60(5):421–31.

Sposito B, Broggi A, Pandolfi L, et al. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell. 2021;184(19):4953-4968.e16.

Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158–72.

Viox EG, Bosinger SE, Douek DC, et al. Harnessing the power of IFN for therapeutic approaches to COVID-19. J Virol. 2024;98(5):e01204-23.

Mansoor S, Butt AR, Bibi A, et al. Expression of IFN-Gamma is significantly reduced during severity of covid-19 infection in hospitalized patients. PloS One. 2023;18(9):e0291332.

González-Sánchez N, Armada-Esmores Z, Llópiz-Casanova L. Propiedades de los interferones y su acción antitumoral. 2017;21(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30432017000300002

Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–58.

de Castro GS, Gama LR, Ramos AF, et al. Post-COVID-19 condition: systemic inflammation and low functional exercise capacity. Front Nutr. 2024;11:1295026.

Choi HS, Choi AY, Kopp JB, et al. Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval. J Korean Med Sci. 2024;39(14):e134.

Wang C, Wang X, Zhang S, et al. Causal relationships between interleukins, interferons and COVID-19 risk: a Mendelian randomization study. Int J Environ Health Res. 2024;34(5):2387–96.

Ng CT, Fong LY, Abdullah MNH. Interferon-gamma (IFN-γ): Reviewing its mechanisms and signaling pathways on the regulation of endothelial barrier function. Cytokine. 2023;166:156208.

Todorović-Raković N, Whitfield JR. Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease. Cytokine. 2021;146:155637.




DOI: https://doi.org/10.24875/10.5281/zenodo.14617070

Enlaces refback

  • No hay ningún enlace refback.